(Q30431132)

21 June 2017

1 reference

title

The biology of interferon-alpha and the clinical significance of anti-interferon antibodies (English)

1 reference

21 June 2017

1 reference

Hanley JP

1

1 reference

21 June 2017

Haydon GH

series ordinal

2

1 reference

21 June 2017

publication date

1 April 1998

1 reference

21 June 2017

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

3-4

1 reference

21 June 2017

page(s)

257-268

1 reference

Virus interference. I. The interferon

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Clinical toxicity of the interferons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Interferons and their actions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non-A, non-B hepatitis treated with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Effects of interferon-alpha on serum hepatitis C virus in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Expression of the 2-5A system during the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Expression of Gene rrg Is Associated with Reversion of NIH 3Tt3 Transformed by LTR-c-H- ras

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Response of glioma cells to interferon-gamma: increase in class II RNA, protein and mixed lymphocyte reaction-stimulating ability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Do the interferons act singly or in combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Immunochemical characterization of human antibodies to lymphobiastoid interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Why do so many cancer patients fail to respond to interferon therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Three human interferon-alpha 2 subvariants disclose structural and functional differences

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Natural human interferon-alpha 2 is O-glycosylated

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199809068563

10.3109/10428199809068563

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference